Sihuan Pharma Trades At 28 Percent Above IPO Target; Analysts Point To Risks
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's Sihuan Pharmaceutical Holdings Group far exceeded its target price in its debut on the Hong Kong stock market, ending the first day with shares trading at 28 percent above the price
You may also be interested in...
Sihuan And Other Leading Chinese Drug Firms Could Get Boost From Current Meeting Of National People's Congress In Beijing
BEIJING - Sihuan Pharmaceutical Holdings Group, based on the tropical Chinese island of Hainan, could see a sharp upward trajectory in earnings over the next three years as it continues to expand its product portfolio through acquisitions fueled by proceeds raised during its initial public offering and a government push to consolidate the Chinese pharmaceutical industry
Sihuan And Other Leading Chinese Drug Firms Could Get Boost From Current Meeting Of National People's Congress In Beijing
BEIJING - Sihuan Pharmaceutical Holdings Group, based on the tropical Chinese island of Hainan, could see a sharp upward trajectory in earnings over the next three years as it continues to expand its product portfolio through acquisitions fueled by proceeds raised during its initial public offering and a government push to consolidate the Chinese pharmaceutical industry
China Biopharma IPOs Skyrocket In 2010 After Freeze Is Lifted
HONG KONG - The number of initial public offerings by pharmaceutical and biotech companies in China continued to rise in 2010, continuing a surge in IPOs that started in mid-2009